Santhera and ReveraGen to Present Efficacy and Safety Data with Vamorolone at 2022 Muscular Dystrophy Association Conference

Pratteln, Switzerland, and Rockville, MD, USA, March 15, 2022
Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce presentations of efficacy and tolerability data with vamorolone in Duchenne muscular dystrophy (DMD) at the 2022 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (March 13-16, 2022, Nashville, TN, USA). A rolling NDA submission to the U.S. FDA for vamorolone for the treatment of DMD is planned to start at the end of March 2022.